Farmas USA (2725/17172)

Zalicus Inc. (ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session.

"We are delighted that Z160 has been selected as a Top 10 Project to Watch,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “The lack of adequate pain control in patients with chronic neuropathic pain represents a significant unmet need and important opportunity for novel agents with improved tolerability, enhanced efficacy, and better long-term safety profiles. We look forward to providing further updates on the clinical development of Z160 over the coming months.”

Responder

#21798

Re: Farmas USA

Seguir

27/11/12 19:40

Noticia de hace unos minutillos la cual nos cuenta lo que ya sabíamos, el añadido de ZLCS a la lista del top 10 de proyectos de Neurociencia a vigilar:
"Zalicus Inc. (Nasdaq: ZLCS) 13.6% HIGHER; announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session. "

Fuente: Streetinsider.com